Well diffusion for antifungal susceptibility testing.
暂无分享,去创建一个
S Magaldi | S Mata-Essayag | C Hartung de Capriles | C Perez | M T Colella | Carolina Olaizola | Yudith Ontiveros | S. Mata‐Essayag | C. Pérez | M. T. Colella | C. Olaizola | S. Magaldi | C. Hartung de Capriles | M. Colella | Yudith Ontiveros | C. H. Capriles | S. Mata-Essayag
[1] M. Piens,et al. Fluconazole susceptibility of Candida isolates from oropharyngeal candidosis , 1997, Mycoses.
[2] J. Rex,et al. Antifungal susceptibility testing: technical advances and potential clinical applications. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[3] J. Martínez-Suárez,et al. Standardization of antifungal susceptibility testing and clinical relevance. , 1998, Medical mycology.
[4] L. Deibis,et al. In Vitro susceptibility of 137 Candida sp. Isolates from HIV positive patients to several antifungal drugs , 2004, Mycopathologia.
[5] M. Klepser. Antifungal Resistance Among Candida Species , 2001, Pharmacotherapy.
[6] J. Vazquez,et al. In vitro antifungal susceptibility methods and clinical implications of antifungal resistance. , 2000, Medical mycology.
[7] M. Pfaller,et al. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: documentation by in vitro susceptibility testing and DNA subtype analysis. , 1994, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[8] M. Ghannoum,et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Labora , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[9] M. Feo. The ‘nascent culture’ and its use , 1978, Mycopathologia.
[10] A. Sierra,et al. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents , 1994, Mycoses.
[11] E. Anaissie,et al. Importance of Candida species other than Candida albicans as opportunistic pathogens. , 1998, Medical mycology.
[12] M. Trautmann,et al. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection , 1994, Journal of clinical microbiology.
[13] C B Moore,et al. High incidence of antifungal drug resistance in Candida tropicalis. , 1996, International journal of antimicrobial agents.
[14] E. Bruck,et al. National Committee for Clinical Laboratory Standards. , 1980, Pediatrics.